References
- Guermonprez P, Saveanu L, Kleijmeer M et al. ER— phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397–402.
- Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD4± T cell lines from naive precursors. Eur Immunol 1995;25: 1206— 11.
- Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8± CTLs from naive precursors. 7 Immunol 1994;153: 996— 1003.
- Mortarini R, Anichini A, Di Nicola M et al. Autologous dendritic cells derived from CD34± progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997;57:5534–41.
- Osugi Y, Vuckovic S, Hart D. Myeloid blood CD11c± dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002;100: 2858— 66.
- Shi Y, Evans J, Rock K. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516–21.
- Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients withB-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52— 8.
- Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517–26.
- Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccinationwith F1t3 ligand expanded dendritic cells for tumor immu-notherapy. Proc Nail Acad Sci USA 2001;98:8809— 14.
- Zaremba S, Barzaga E, Zhu M et al. Identification of an enhanceragonist cytotoxic T lymphocyte peptide from human carci-noembryonic antigen. Cancer Res 1997;57:4570— 7.
- Salazar E, Zaremba S, Arlen PM et al. Agonist peptide from acytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tcl-type cytokines and in-creases tyrosine phosphorylation more efficiently than cognate peptide. Int y Cancer 2000;85:829–38.
- Rini BI, Paintal A, Vogelzang NJ. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. 7 Immunother 2002;25: 269— 77.
- Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. Immunol 2001;167:7150–6.
- Fong L, Rue tit CL, Brockstedt D et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. y Immunol 1997;159:3113— 7.
- Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002;99:1676— 82.
- Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. 7 Clin Invest 2004;113:774–83.
- Kumamoto T, Huang EK, Paek HJ et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol 2002;20:64— 9.
- Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompat-ibility complex class I products and peripheral CD8± T cell tolerance. 7 Exp Med 2002;196:1627— 38.